Ticker

Shares of Passage Bio, Inc. (NASDAQ: PASG - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the four ratings firms that are currently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating and three have assigned a buy rating to the company. The average

Enrolled first three FTD-GRN patients in Cohort 3 of ongoing upliFT-D study Treated first FTD-C9orf72 patient with Dose 2 PBFT02 in Cohort 4 of upliFT-D study On track to report updated interim safety and biomarker data from upliFT-D and obtain regulatory feedback on FTD-GRN registrational trial design in 1H 2026 Advancing differentiated preclinical program for Huntington's with clinical candidate selection expected…

PHILADELPHIA, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced management will participate in the following upcoming investor conferences: Oppenheimer 36 th Annual Healthcare Life Sciences Conference Format: Management will participate in a presentation and…

Passage Bio, Inc. (NASDAQ: PASG - Get Free Report) has been assigned an average rating of "Moderate Buy" from the four brokerages that are currently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation and three have issued a buy recommendation on the company. The average twelve-month price

Passage Bio, Inc. (NASDAQ: PASG - Get Free Report) has been given an average rating of "Moderate Buy" by the four research firms that are currently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating and three have issued a buy rating on the company. The average twelve-month